Skip to main content
Erschienen in: Drugs & Aging 2/2019

11.12.2018 | Review Article

Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia

verfasst von: Stephanie L. Harrison, Monica Cations, Tiffany Jessop, Sarah N. Hilmer, Mouna Sawan, Henry Brodaty

Erschienen in: Drugs & Aging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Psychotropic medications have a high risk of serious adverse events and small effect size for changed behaviours for people with dementia. Non-pharmacological approaches are recommended as first-line treatment for changed behaviours, yet psychotropic medications remain highly prevalent in long-term aged care settings. This narrative review describes the current evidence regarding deprescribing psychotropic medications for people with dementia in long-term care. Deprescribing psychotropic medications can be achieved without harm to the person with dementia, and most people experience no withdrawal symptoms. Interventions to deprescribe psychotropic medications should be multifactorial, including lowering the dose of the medication over time, educational interventions and psychological support. However, implementing this is a significant challenge due to the overreliance on psychotropic medications for behavioural management in long-term aged care. Facilitators to deprescribing psychotropic medications in long-term care include multidisciplinary teams with adequate training, education and managerial support, engaging residents and families and change ‘champions’. Deprescribing practices should be person-centred, and an individualised deprescribing protocol should be in place, followed by careful monitoring of the individual. The person with dementia and their family, general practitioner, pharmacist, and allied health and direct care staff should all be involved throughout the deprescribing process. Direct care staff need adequate support, education and training, so they can effectively help the individual and implement person-centred approaches in the absence of psychotropic medications. Effective communication between residents and staff and amongst staff is consistently shown to be an important factor for deciding whether deprescribing of a medication should occur and the successful implementation of deprescribing psychotropic medications.
Literatur
2.
Zurück zum Zitat Laver K, Cumming RG, Dyer SM, Agar MR, Anstey KJ, Beattie E, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016;204(5):191–3.CrossRefPubMed Laver K, Cumming RG, Dyer SM, Agar MR, Anstey KJ, Beattie E, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016;204(5):191–3.CrossRefPubMed
3.
Zurück zum Zitat National Collaborating Centre for Mental Health. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Leicester: British Psychological Society; 2007. National Collaborating Centre for Mental Health. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Leicester: British Psychological Society; 2007.
4.
Zurück zum Zitat Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27.PubMedPubMedCentral Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27.PubMedPubMedCentral
5.
Zurück zum Zitat Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.CrossRefPubMed Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.CrossRefPubMed
6.
Zurück zum Zitat Dyer SM, Harrison SL, Laver K, Whitehead C, Crotty M. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018;30(3):295–309.CrossRefPubMed Dyer SM, Harrison SL, Laver K, Whitehead C, Crotty M. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018;30(3):295–309.CrossRefPubMed
8.
Zurück zum Zitat Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:Cd007726.PubMed Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:Cd007726.PubMed
9.
Zurück zum Zitat Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, Briesacher BA, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013;14(12):895–900.CrossRefPubMed Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, Briesacher BA, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013;14(12):895–900.CrossRefPubMed
10.
Zurück zum Zitat Janus SI, van Manen JG, Zuidema SU, Snijder C, Drossaert CH, Ijzerman MJ. Reasons for (not) discontinuing antipsychotics in dementia. Psychogeriatrics. 2018;18(1):13–20.CrossRefPubMed Janus SI, van Manen JG, Zuidema SU, Snijder C, Drossaert CH, Ijzerman MJ. Reasons for (not) discontinuing antipsychotics in dementia. Psychogeriatrics. 2018;18(1):13–20.CrossRefPubMed
11.
Zurück zum Zitat Pulsford D, Duxbury J. Aggressive behaviour by people with dementia in residential care settings: a review. J Psychiatr Ment Health Nurs. 2006;13(5):611–8.CrossRefPubMed Pulsford D, Duxbury J. Aggressive behaviour by people with dementia in residential care settings: a review. J Psychiatr Ment Health Nurs. 2006;13(5):611–8.CrossRefPubMed
12.
Zurück zum Zitat Cubit K, Farrell G, Robinson A, Myhill M. A survey of the frequency and impact of behaviours of concern in dementia on residential aged care staff. Australas J Ageing. 2007;26(2):64–70.CrossRef Cubit K, Farrell G, Robinson A, Myhill M. A survey of the frequency and impact of behaviours of concern in dementia on residential aged care staff. Australas J Ageing. 2007;26(2):64–70.CrossRef
13.
Zurück zum Zitat Hoe J, Hancock G, Livingston G, Orrell M. Quality of life of people with dementia in residential care homes. Br J Psychiatry. 2018;188(5):460–4.CrossRef Hoe J, Hancock G, Livingston G, Orrell M. Quality of life of people with dementia in residential care homes. Br J Psychiatry. 2018;188(5):460–4.CrossRef
14.
Zurück zum Zitat Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.CrossRefPubMed Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.CrossRefPubMed
15.
Zurück zum Zitat Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16(2):Cd008191. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16(2):Cd008191.
16.
Zurück zum Zitat Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. J Am Med Assoc. 2014;311(7):682–91.CrossRef Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. J Am Med Assoc. 2014;311(7):682–91.CrossRef
17.
Zurück zum Zitat Buterbaugh WM, Jamrose T, Lazzara J, Honaker L, Thomas CJ. Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD). Ment Health Clin. 2014;4(4):183–8.CrossRef Buterbaugh WM, Jamrose T, Lazzara J, Honaker L, Thomas CJ. Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD). Ment Health Clin. 2014;4(4):183–8.CrossRef
18.
Zurück zum Zitat Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.CrossRefPubMedPubMedCentral Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11.CrossRefPubMed Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11.CrossRefPubMed
20.
Zurück zum Zitat Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services United Kingdom Department of Health From the website. 2009. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services United Kingdom Department of Health From the website. 2009.
21.
Zurück zum Zitat Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.CrossRefPubMed Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.CrossRefPubMed
22.
Zurück zum Zitat Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2018;2:1–8. Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2018;2:1–8.
23.
Zurück zum Zitat Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297–309.CrossRefPubMedPubMedCentral Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297–309.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimer’s Dis Rep. 2018;2(1):287–312. Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimer’s Dis Rep. 2018;2(1):287–312.
25.
Zurück zum Zitat Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc. 2005;294(15):1934–43.CrossRef Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc. 2005;294(15):1934–43.CrossRef
26.
Zurück zum Zitat Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.CrossRefPubMedPubMedCentral Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;4:CD007726. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;4:CD007726.
28.
Zurück zum Zitat Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pvy055.CrossRef Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pvy055.CrossRef
29.
Zurück zum Zitat Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioural and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.CrossRefPubMed Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioural and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.CrossRefPubMed
30.
Zurück zum Zitat Gustafsson M, Isaksson U, Karlsson S, Sandman P-O, Lövheim H. Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol. 2016;72(8):987–94.CrossRefPubMed Gustafsson M, Isaksson U, Karlsson S, Sandman P-O, Lövheim H. Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol. 2016;72(8):987–94.CrossRefPubMed
31.
Zurück zum Zitat Jacquin-Piques A, Sacco G, Tavassoli N, Rouaud O, Bejot Y, Giroud M, et al. Psychotropic drug prescription in patients with dementia: nursing home residents versus patients living at home. J Alzheimer’s Dis. 2016;49(3):671–80.CrossRef Jacquin-Piques A, Sacco G, Tavassoli N, Rouaud O, Bejot Y, Giroud M, et al. Psychotropic drug prescription in patients with dementia: nursing home residents versus patients living at home. J Alzheimer’s Dis. 2016;49(3):671–80.CrossRef
32.
Zurück zum Zitat Janus SI, van Manen JG, IJzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28(11):1775–90.CrossRefPubMed Janus SI, van Manen JG, IJzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28(11):1775–90.CrossRefPubMed
33.
Zurück zum Zitat Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across us nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentral Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across us nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Shah SM, Carey IM, Harris T, DeWilde S, Cook DG. Quality of prescribing in care homes and the community in England and Wales. Br J Gen Pract. 2012;62(598):e329–36.CrossRefPubMedPubMedCentral Shah SM, Carey IM, Harris T, DeWilde S, Cook DG. Quality of prescribing in care homes and the community in England and Wales. Br J Gen Pract. 2012;62(598):e329–36.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18(12):1078–92.CrossRefPubMedPubMedCentral Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18(12):1078–92.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Nørgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimer’s Dis. 2017;56(2):707–16.CrossRef Nørgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimer’s Dis. 2017;56(2):707–16.CrossRef
37.
Zurück zum Zitat Rojas-Fernandez C, Mikhail M, Brown SG. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. Ann Pharmacother. 2014;48(4):438–46.CrossRefPubMed Rojas-Fernandez C, Mikhail M, Brown SG. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. Ann Pharmacother. 2014;48(4):438–46.CrossRefPubMed
38.
Zurück zum Zitat van der Spek K, Gerritsen DL, Smalbrugge M, Nelissen-Vrancken MH, Wetzels RB, Smeets CH, et al. Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. Int Psychogeriatr. 2016;28(10):1589–95.CrossRefPubMed van der Spek K, Gerritsen DL, Smalbrugge M, Nelissen-Vrancken MH, Wetzels RB, Smeets CH, et al. Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. Int Psychogeriatr. 2016;28(10):1589–95.CrossRefPubMed
39.
Zurück zum Zitat de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. BioMed Res Int. 2015;2015:218980.PubMedPubMedCentral de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. BioMed Res Int. 2015;2015:218980.PubMedPubMedCentral
40.
Zurück zum Zitat Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42.CrossRefPubMed Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42.CrossRefPubMed
41.
Zurück zum Zitat Edvardsson D, Sandman PO, Borell L. Implementing national guidelines for person-centered care of people with dementia in residential aged care: effects on perceived person-centeredness, staff strain, and stress of conscience. Int Psychogeriatr. 2014;26(7):1171–9.CrossRefPubMed Edvardsson D, Sandman PO, Borell L. Implementing national guidelines for person-centered care of people with dementia in residential aged care: effects on perceived person-centeredness, staff strain, and stress of conscience. Int Psychogeriatr. 2014;26(7):1171–9.CrossRefPubMed
42.
Zurück zum Zitat Daly RL, Bunn F, Goodman C. Shared decision-making for people living with dementia in extended care settings: a systematic review. BMJ Open. 2018;8(6):e018977.CrossRefPubMedPubMedCentral Daly RL, Bunn F, Goodman C. Shared decision-making for people living with dementia in extended care settings: a systematic review. BMJ Open. 2018;8(6):e018977.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Chenoweth L, Forbes I, Fleming R, King MT, Stein-Parbury J, Luscombe G, et al. PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia. Int Psychogeriatr. 2014;26(7):1147–60.CrossRefPubMed Chenoweth L, Forbes I, Fleming R, King MT, Stein-Parbury J, Luscombe G, et al. PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia. Int Psychogeriatr. 2014;26(7):1147–60.CrossRefPubMed
44.
Zurück zum Zitat Moniz Cook ED, Swift K, James I, Malouf R, De Vugt M, Verhey F. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev. 2012;15(2):Cd006929. Moniz Cook ED, Swift K, James I, Malouf R, De Vugt M, Verhey F. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev. 2012;15(2):Cd006929.
45.
Zurück zum Zitat Fraker J, Kales HC, Blazek M, Kavanagh J, Gitlin LN. The role of the occupational therapist in the management of neuropsychiatric symptoms of dementia in clinical settings. Occup Ther Health Care. 2014;28(1):4–20.CrossRefPubMedPubMedCentral Fraker J, Kales HC, Blazek M, Kavanagh J, Gitlin LN. The role of the occupational therapist in the management of neuropsychiatric symptoms of dementia in clinical settings. Occup Ther Health Care. 2014;28(1):4–20.CrossRefPubMedPubMedCentral
46.
47.
Zurück zum Zitat van der Steen J, Smaling H, Bruinsma M, Scholten R, Vink A. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7:CD003477.PubMed van der Steen J, Smaling H, Bruinsma M, Scholten R, Vink A. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7:CD003477.PubMed
48.
Zurück zum Zitat Gerdner LA. Effects of individualized versus classical “relaxation” music on the frequency of agitation in elderly persons with Alzheimer’s disease and related disorders. Int Psychogeriatr. 2000;12(1):49–65.CrossRefPubMed Gerdner LA. Effects of individualized versus classical “relaxation” music on the frequency of agitation in elderly persons with Alzheimer’s disease and related disorders. Int Psychogeriatr. 2000;12(1):49–65.CrossRefPubMed
49.
Zurück zum Zitat Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.CrossRefPubMed Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.CrossRefPubMed
50.
Zurück zum Zitat Tsoi KKF, Chan JYC, Ng YM, Lee MMY, Kwok TCY, Wong SYS. Receptive music therapy is more effective than interactive music therapy to relieve behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. J Am Med Dir Assoc. 2018;19(7):568–76.CrossRefPubMed Tsoi KKF, Chan JYC, Ng YM, Lee MMY, Kwok TCY, Wong SYS. Receptive music therapy is more effective than interactive music therapy to relieve behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. J Am Med Dir Assoc. 2018;19(7):568–76.CrossRefPubMed
51.
Zurück zum Zitat Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–8.CrossRefPubMedPubMedCentral Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–8.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Woods B, O’Philbin L, Farrell EM, Spector AE, Orrell M. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018;3:Cd001120.PubMed Woods B, O’Philbin L, Farrell EM, Spector AE, Orrell M. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018;3:Cd001120.PubMed
53.
Zurück zum Zitat Forrester LT, Maayan N, Orrell M, Spector AE, Buchan LD, Soares-Weiser K. Aromatherapy for dementia. Cochrane Database Syst Rev. 2014;25(2):Cd003150. Forrester LT, Maayan N, Orrell M, Spector AE, Buchan LD, Soares-Weiser K. Aromatherapy for dementia. Cochrane Database Syst Rev. 2014;25(2):Cd003150.
54.
Zurück zum Zitat Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018;361:k1675.CrossRefPubMedPubMedCentral Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018;361:k1675.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;15(4):Cd006489. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;15(4):Cd006489.
57.
Zurück zum Zitat Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317–25.CrossRefPubMed Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317–25.CrossRefPubMed
58.
Zurück zum Zitat Low L-F, Brodaty H, Goodenough B, Spitzer P, Bell J-P, Fleming R, et al. The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) study: cluster randomised trial of humour therapy in nursing homes. BMJ Open. 2013;3:e002072.CrossRefPubMedPubMedCentral Low L-F, Brodaty H, Goodenough B, Spitzer P, Bell J-P, Fleming R, et al. The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) study: cluster randomised trial of humour therapy in nursing homes. BMJ Open. 2013;3:e002072.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Brodaty H, Low L-F, Liu Z, Fletcher J, Roast J, Goodenough B, et al. Successful ingredients in the SMILE study: resident, staff, and management factors influence the effects of humor therapy in residential aged care. Am J Geriatr Psychiatry. 2014;22(12):1427–37.CrossRefPubMed Brodaty H, Low L-F, Liu Z, Fletcher J, Roast J, Goodenough B, et al. Successful ingredients in the SMILE study: resident, staff, and management factors influence the effects of humor therapy in residential aged care. Am J Geriatr Psychiatry. 2014;22(12):1427–37.CrossRefPubMed
60.
Zurück zum Zitat Verbeek H, Zwakhalen SM, van Rossum E, Ambergen T, Kempen GI, Hamers JP. Effects of small-scale, home-like facilities in dementia care on residents’ behavior, and use of physical restraints and psychotropic drugs: a quasi-experimental study. Int Psychogeriatr. 2014;26(4):657–68.CrossRefPubMed Verbeek H, Zwakhalen SM, van Rossum E, Ambergen T, Kempen GI, Hamers JP. Effects of small-scale, home-like facilities in dementia care on residents’ behavior, and use of physical restraints and psychotropic drugs: a quasi-experimental study. Int Psychogeriatr. 2014;26(4):657–68.CrossRefPubMed
61.
Zurück zum Zitat Harrison SL, Bradley C, Milte R, Liu E, Kouladjian O’Donnell L, Hilmer SN, et al. Psychotropic medications in older people in residential care facilities and associations with quality of life: a cross-sectional study. BMC Geriatr. 2018;18(1):60.CrossRefPubMedPubMedCentral Harrison SL, Bradley C, Milte R, Liu E, Kouladjian O’Donnell L, Hilmer SN, et al. Psychotropic medications in older people in residential care facilities and associations with quality of life: a cross-sectional study. BMC Geriatr. 2018;18(1):60.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Health Care Financing Administration. Survey procedures and interpretive guidelines for skilled nursing facilities and intermediate care facilities. Baltimore; 1990. Health Care Financing Administration. Survey procedures and interpretive guidelines for skilled nursing facilities and intermediate care facilities. Baltimore; 1990.
63.
Zurück zum Zitat Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry. 1996;18(2):77–94.CrossRefPubMed Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry. 1996;18(2):77–94.CrossRefPubMed
64.
Zurück zum Zitat Llorente MD, Olsen EJ, Leyva O, Silverman MA, Lewis JE, Rivero J. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc. 1998;46(2):198–201.CrossRefPubMed Llorente MD, Olsen EJ, Leyva O, Silverman MA, Lewis JE, Rivero J. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc. 1998;46(2):198–201.CrossRefPubMed
65.
Zurück zum Zitat Hughes CM, Lapane KL, Mor V, Ikegami N, Jonsson PV, Ljunggren G, et al. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc. 2000;48(8):931–7.CrossRefPubMed Hughes CM, Lapane KL, Mor V, Ikegami N, Jonsson PV, Ljunggren G, et al. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc. 2000;48(8):931–7.CrossRefPubMed
66.
Zurück zum Zitat Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.CrossRefPubMed Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.CrossRefPubMed
68.
Zurück zum Zitat Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.CrossRefPubMedPubMedCentral Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Singh RR, Nayak R. Impact of FDA black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2016;29(5):495–502.CrossRefPubMed Singh RR, Nayak R. Impact of FDA black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2016;29(5):495–502.CrossRefPubMed
70.
Zurück zum Zitat Szczepura A, Wild D, Khan AJ, Owen DW, Palmer T, Muhammad T, et al. Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period. BMJ Open. 2016;6(9):e009882.CrossRefPubMedPubMedCentral Szczepura A, Wild D, Khan AJ, Owen DW, Palmer T, Muhammad T, et al. Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period. BMJ Open. 2016;6(9):e009882.CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2:Cd009095.PubMed Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2:Cd009095.PubMed
73.
Zurück zum Zitat Register Federal. Medicare and Medicaid programs; reform of requirements for long-term care facilities. Final rule. Fed Regist. 2016;81(192):68688–872. Register Federal. Medicare and Medicaid programs; reform of requirements for long-term care facilities. Final rule. Fed Regist. 2016;81(192):68688–872.
74.
75.
Zurück zum Zitat Kallio SE, Kiiski A, Airaksinen MSA, Mantyla AT, Kumpusalo-Vauhkonen AEJ, Jarvensivu TP, et al. Community pharmacists’ contribution to medication reviews for older adults: a systematic review. J Am Geriatr Soc. 2018;66(8):1613–20.CrossRefPubMed Kallio SE, Kiiski A, Airaksinen MSA, Mantyla AT, Kumpusalo-Vauhkonen AEJ, Jarvensivu TP, et al. Community pharmacists’ contribution to medication reviews for older adults: a systematic review. J Am Geriatr Soc. 2018;66(8):1613–20.CrossRefPubMed
77.
Zurück zum Zitat Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86.CrossRefPubMed Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86.CrossRefPubMed
78.
Zurück zum Zitat Thiruchelvam K, Hasan SS, Wong PS, Kairuz T. Residential aged care medication review to improve the quality of medication use: a systematic review. J Am Med Dir Assoc. 2017;18(1):87.e1–.e14. Thiruchelvam K, Hasan SS, Wong PS, Kairuz T. Residential aged care medication review to improve the quality of medication use: a systematic review. J Am Med Dir Assoc. 2017;18(1):87.e1–.e14.
80.
Zurück zum Zitat Sawan MJ, Jeon YH, Fois RJ, Chen TF. A qualitative study exploring visible components of organizational culture: what influences the use of psychotropic medicines in nursing homes? Int Psychogeriatr. 2016;28(10):1725–35.CrossRefPubMed Sawan MJ, Jeon YH, Fois RJ, Chen TF. A qualitative study exploring visible components of organizational culture: what influences the use of psychotropic medicines in nursing homes? Int Psychogeriatr. 2016;28(10):1725–35.CrossRefPubMed
81.
Zurück zum Zitat Rendina N, Brodaty H, Draper B, Peisah C, Brugue E. Substitute consent for nursing home residents prescribed psychotropic medication. Int J Geriatr Psychiatry. 2009;24(3):226–31.CrossRefPubMed Rendina N, Brodaty H, Draper B, Peisah C, Brugue E. Substitute consent for nursing home residents prescribed psychotropic medication. Int J Geriatr Psychiatry. 2009;24(3):226–31.CrossRefPubMed
82.
Zurück zum Zitat Plakiotis C, Bell JS, Jeon YH, Pond D, O’Connor DW. Deprescribing psychotropic medications in aged care facilities: the potential role of family members. Adv Exp Med Biol. 2015;821:29–43.CrossRefPubMed Plakiotis C, Bell JS, Jeon YH, Pond D, O’Connor DW. Deprescribing psychotropic medications in aged care facilities: the potential role of family members. Adv Exp Med Biol. 2015;821:29–43.CrossRefPubMed
83.
Zurück zum Zitat Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497–507.CrossRefPubMedPubMedCentral Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497–507.CrossRefPubMedPubMedCentral
84.
Zurück zum Zitat Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600.e7.CrossRefPubMed Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600.e7.CrossRefPubMed
85.
Zurück zum Zitat Chenoweth L, Jessop T, Harrison F, Cations M, Cook J, Brodaty H. Critical contextual elements in facilitating and achieving success with a person-centred care intervention to support antipsychotic deprescribing for older people in long-term care. BioMed Res Int. 2018;2018:12.CrossRef Chenoweth L, Jessop T, Harrison F, Cations M, Cook J, Brodaty H. Critical contextual elements in facilitating and achieving success with a person-centred care intervention to support antipsychotic deprescribing for older people in long-term care. BioMed Res Int. 2018;2018:12.CrossRef
86.
Zurück zum Zitat Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398–403.CrossRefPubMed Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398–403.CrossRefPubMed
87.
Zurück zum Zitat Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756–61.CrossRefPubMedPubMedCentral Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756–61.CrossRefPubMedPubMedCentral
88.
Zurück zum Zitat Lawrence V, Fossey J, Ballard C, Moniz-Cook E, Murray J. Improving quality of life for people with dementia in care homes: making psychosocial interventions work. Br J Psychiatry. 2012;201(5):344–51.CrossRefPubMed Lawrence V, Fossey J, Ballard C, Moniz-Cook E, Murray J. Improving quality of life for people with dementia in care homes: making psychosocial interventions work. Br J Psychiatry. 2012;201(5):344–51.CrossRefPubMed
89.
Zurück zum Zitat van der Spek K, Koopmans R, Smalbrugge M, Nelissen-Vrancken M, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018;47(3):430–7.CrossRefPubMed van der Spek K, Koopmans R, Smalbrugge M, Nelissen-Vrancken M, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018;47(3):430–7.CrossRefPubMed
90.
Zurück zum Zitat Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–7.CrossRefPubMed Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–7.CrossRefPubMed
92.
Zurück zum Zitat Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73(8):927–35.CrossRefPubMed Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73(8):927–35.CrossRefPubMed
93.
Zurück zum Zitat Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13(7):919–34.CrossRefPubMed Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13(7):919–34.CrossRefPubMed
94.
Zurück zum Zitat Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–19.CrossRefPubMed Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–19.CrossRefPubMed
95.
Zurück zum Zitat Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallieres A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332–42.CrossRefPubMed Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallieres A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332–42.CrossRefPubMed
96.
Zurück zum Zitat Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract. 2006;56(533):958–63.PubMedPubMedCentral Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract. 2006;56(533):958–63.PubMedPubMedCentral
97.
Zurück zum Zitat Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimer’s Dis. 2017;58(3):725–33.CrossRef Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimer’s Dis. 2017;58(3):725–33.CrossRef
98.
Zurück zum Zitat Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81.CrossRefPubMed Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81.CrossRefPubMed
99.
Zurück zum Zitat Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.CrossRefPubMed Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.CrossRefPubMed
100.
Zurück zum Zitat Reeve E, Bell JS, Hilmer SN. Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. Curr Clin Pharmacol. 2015;10(3):168–77.CrossRefPubMed Reeve E, Bell JS, Hilmer SN. Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. Curr Clin Pharmacol. 2015;10(3):168–77.CrossRefPubMed
101.
Zurück zum Zitat Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.CrossRefPubMedPubMedCentral Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.CrossRefPubMedPubMedCentral
102.
Zurück zum Zitat Turner JP, Edwards S, Stanners M, Shakib S, Bell JS. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open. 2016;6(3):e009781.CrossRefPubMedPubMedCentral Turner JP, Edwards S, Stanners M, Shakib S, Bell JS. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open. 2016;6(3):e009781.CrossRefPubMedPubMedCentral
103.
Zurück zum Zitat Zhang Y, Letuchy EM, Carnahan RM. Where are antipsychotics prescribed in nursing homes initiated? J Am Geriatr Soc. 2018;66(6):1082–8.CrossRefPubMed Zhang Y, Letuchy EM, Carnahan RM. Where are antipsychotics prescribed in nursing homes initiated? J Am Geriatr Soc. 2018;66(6):1082–8.CrossRefPubMed
104.
Zurück zum Zitat Sawan M, Chen T, Jeon YH, Hilmer SN. Interventions to reduce antipsychotic prescribing in nursing homes must cross healthcare silos. J Am Geriatr Soc. 2018;66(6):1235–6.CrossRefPubMed Sawan M, Chen T, Jeon YH, Hilmer SN. Interventions to reduce antipsychotic prescribing in nursing homes must cross healthcare silos. J Am Geriatr Soc. 2018;66(6):1235–6.CrossRefPubMed
105.
Zurück zum Zitat Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.CrossRefPubMed Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.CrossRefPubMed
106.
Zurück zum Zitat Kalogianis MJ, Wimmer BC, Turner JP, Tan EC, Emery T, Robson L, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Soc Admin Pharm. 2016;12(5):784–8.CrossRef Kalogianis MJ, Wimmer BC, Turner JP, Tan EC, Emery T, Robson L, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Soc Admin Pharm. 2016;12(5):784–8.CrossRef
107.
Zurück zum Zitat Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.CrossRefPubMed Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.CrossRefPubMed
108.
Zurück zum Zitat Sawan M, Jeon YH, Chen TF. Shaping the use of psychotropic medicines in nursing homes: a qualitative study on organisational culture. Soc Sci Med. 2018;202:70–8.CrossRefPubMed Sawan M, Jeon YH, Chen TF. Shaping the use of psychotropic medicines in nursing homes: a qualitative study on organisational culture. Soc Sci Med. 2018;202:70–8.CrossRefPubMed
109.
Zurück zum Zitat Sawan M, Jeon YH, Fois RA, Chen TF. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Soc Admin Pharm. 2017;13(3):513–23.CrossRef Sawan M, Jeon YH, Fois RA, Chen TF. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Soc Admin Pharm. 2017;13(3):513–23.CrossRef
110.
Zurück zum Zitat Jennings AA, Foley T, Walsh KA, Coffey A, Browne JP, Bradley CP. General practitioners’ knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: a mixed-methods systematic review. Int J Geriatr Psychiatry. 2018;7(1):62. Jennings AA, Foley T, Walsh KA, Coffey A, Browne JP, Bradley CP. General practitioners’ knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: a mixed-methods systematic review. Int J Geriatr Psychiatry. 2018;7(1):62.
111.
Zurück zum Zitat Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS One. 2016;11(4):e0151066.CrossRefPubMedPubMedCentral Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS One. 2016;11(4):e0151066.CrossRefPubMedPubMedCentral
112.
113.
114.
Zurück zum Zitat Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–28.CrossRefPubMed Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–28.CrossRefPubMed
115.
Zurück zum Zitat Olivieri-Mui BL, Devlin JW, Ochoa A, Schenck D, Briesacher B. Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. Aging Ment Health. 2018;22(4):544–9.CrossRefPubMed Olivieri-Mui BL, Devlin JW, Ochoa A, Schenck D, Briesacher B. Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. Aging Ment Health. 2018;22(4):544–9.CrossRefPubMed
116.
Zurück zum Zitat Anrys P, Strauven G, Boland B, Dalleur O, Declercq A, Degryse J-M, et al. Collaborative approach to Optimise MEdication use for Older people in Nursing homes (COME-ON): study protocol of a cluster controlled trial. Implement Sci. 2015;11(1):35.CrossRef Anrys P, Strauven G, Boland B, Dalleur O, Declercq A, Degryse J-M, et al. Collaborative approach to Optimise MEdication use for Older people in Nursing homes (COME-ON): study protocol of a cluster controlled trial. Implement Sci. 2015;11(1):35.CrossRef
117.
Zurück zum Zitat Mahlknecht A, Nestler N, Bauer U, Schüßler N, Schuler J, Scharer S, et al. Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol. BMC Geriatr. 2017;17(1):24.CrossRefPubMedPubMedCentral Mahlknecht A, Nestler N, Bauer U, Schüßler N, Schuler J, Scharer S, et al. Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol. BMC Geriatr. 2017;17(1):24.CrossRefPubMedPubMedCentral
Metadaten
Titel
Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia
verfasst von
Stephanie L. Harrison
Monica Cations
Tiffany Jessop
Sarah N. Hilmer
Mouna Sawan
Henry Brodaty
Publikationsdatum
11.12.2018
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0623-6

Weitere Artikel der Ausgabe 2/2019

Drugs & Aging 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.